Literature DB >> 27755781

Intensity modulated radiation therapy in the treatment of esophageal cancer.

Johnny C Yap1, Harish K Malhotra1, Gary Y Yang1.   

Abstract

Chemoradiation plays a core role in the definitive and preoperative management of esophageal cancer. Remarkable advances in technology now allow for the implementation of intensity modulated radiation therapy (IMRT) to minimize normal organ damage and to maximize coverage of tumorous targets. While IMRT is commonly accepted in the treatment of prostate and head and neck cancers, there have been clinical and dosimetric studies supporting the use of IMRT in esophagus cancer. In addition, the IMRT technique was recently enhanced by the availability of volumetric intensity modulated arc therapy (VMAT). VMAT may allow for faster delivery of IMRT with the advantage of normal organ protection compared to the stop-and-shoot IMRT, with faster delivery time and reduced monitor units. This review summarizes the use of chemoradiation in esophageal cancer, discusses current dosimetric data and clinical outcomes with the use of IMRT, and reviews IMRT as part of multi-modality treatment in esophageal cancer. © Tianjin Lung Cancer Institute and Blackwell Publishing Asia Pty. Ltd.

Entities:  

Keywords:  Chemoradiotherapy; esophageal cancer; intensity modulated radiation therapy

Year:  2010        PMID: 27755781     DOI: 10.1111/j.1759-7714.2010.00017.x

Source DB:  PubMed          Journal:  Thorac Cancer        ISSN: 1759-7706            Impact factor:   3.500


  2 in total

1.  Dickkopf-1 is involved in invasive growth of esophageal cancer cells.

Authors:  Shujun Li; Xuebo Qin; Bin Liu; Liya Sun; Xun Zhang; Zhigang Li; Baoen Shan; Jiacong You; Qinghua Zhou
Journal:  J Mol Histol       Date:  2011-09-10       Impact factor: 2.611

Review 2.  Adenoid cystic carcinoma of the esophagus: report of two cases and review of the Chinese literature.

Authors:  Xu-feng Guo; Ten Mao; Zhi-tao Gu; Wen-tao Fang; Wen-hu Chen; Jin-chen Shao
Journal:  Diagn Pathol       Date:  2012-12-13       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.